 This study analyzed the effectiveness of compounded recombinant human epidermal growth factor, IHEGF, on skin lesions through a case series involving 77 patients with various pathologies, including type 2 diabetes mellitus and chronic venous insufficiency. The interventions used included topical IHEGF with an average time between cures of 36 hours and a mean follow-up of 6.6 weeks. Results showed that the treatment was effective, comfortable and tolerable, with about 43.3% of included venous ulcers having a greater than 40% cure rate in four weeks. However, limitations include heterogeneity of the included pathologies and limited time follow-up in some cases. Further studies are needed to establish more precise concentrations, indications, and clinical guidelines for the use of topical IHEGF. This article was authored by Shordi Esquiral Corsa and Elizabeth Herrera Villar.